Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies
Excerpt:
...potent inhibitory activity of sorafenib and sunitinib was observed against FLT3 (IC50s of 4 and 12 nmol/L, respectively) and PDGFRα (0.5 and 3 nmol/L), neither compound exhibited high potency against KIT (59 and 56 nmol/L) or FGFR1 (>100 and >100 nmol/L; ref. Fig. 2B and Table 1).